Novel, non-invasive imaging approach to identify patients with advanced non-small cell lung cancer at risk of hyperprogressive disease with immune checkpoint blockade
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Purpose: Hyperprogression is an atypical response pattern to immune checkpoint inhibition that has been described within non-small cell lung cancer (NSCLC). The paradoxical acceleration of tumor growth after immunotherapy has been associated with significantly shortened survival, and currently, there are no clinically validated biomarkers to identify patients at risk of hyperprogression. Experimental design: A total of 109 patients with advanced NSCLC who underwent monotherapy with Programmed cell death protein-1 (PD1)/Programmed death-ligand-1 (PD-L1) inhibitors were included in the study. Using RECIST measurements, we divided the patients into responders (n=50) (complete/partial response or stable disease) and non-responders (n=59) (progressive disease). Tumor growth kinetics were used to further identify hyperprogressors (HPs, n=19) among non-responders. Patients were randomized into a training set (D 1=30) and a test set (D 2=79) with the essential caveat that HPs were evenly distributed among the two sets. A total of 198 radiomic textural patterns from within and around the target nodules and features relating to tortuosity of the nodule associated vasculature were extracted from the pretreatment CT scans. Results: The random forest classifier using the top features associated with hyperprogression was able to distinguish between HP and other radiographical response patterns with an area under receiver operating curve of 0.85±0.06 in the training set (D 1=30) and 0.96 in the validation set (D 2=79). These features included one peritumoral texture feature from 5 to 10 mm outside the tumor and two nodule vessel-related tortuosity features. Kaplan-Meier survival curves showed a clear stratification between classifier predicted HPs versus non-HPs for overall survival (D 2: HR=2.66, 95% CI 1.27 to 5.55; p=0.009). Conclusions: Our study suggests that image-based radiomics markers extracted from baseline CTs of advanced NSCLC treated with PD-1/PD-L1 inhibitors may help identify patients at risk of hyperprogressions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Silhouettes: A graphical aid to the interpretation and validation of cluster analysis
Rousseeuw, P. J. (1987) · Journal of Computational and Applied Mathematics · doi:10.1016/0377-0427(87)90125-7 · Cited by 21,392
Radiomics: Images Are More than Pictures, They Are Data
Gillies, R. J., Kinahan, P. E., & Hricak, H. (2016) · Radiology · doi:10.1148/radiol.2015151169 · Cited by 8,421
Sun, R., Limkin, E. J., Vakalopoulou, M., Dercle, L., Champiat, S., Han, S. R., Verlingue, L., Brandao, D., Lancia, A., Ammari, S., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30413-3 · Cited by 1,236
Ferrara, R., Mezquita, L., Texier, M., Lahmar, J., Audigier-Valette, C., Tessonnier, L., Mazieres, J., Zalcman, G., Brosseau, S., Le Moulec, S., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3676 · Cited by 720
CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma
Coroller, T. P., Grossmann, P., Hou, Y., Rios Velazquez, E., Leijenaar, R. T. H., Hermann, G., Lambin, P., Haibe-Kains, B., Mak, R. H., & Aerts, H. J. W. L. (2015) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2015.02.015 · Cited by 695
Khorrami, M., Prasanna, P., Gupta, A., Patil, P., Velu, P. D., Thawani, R., Corredor, G., Alilou, M., Bera, K., Fu, P., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0476 · Cited by 297
Self-citationRadiogenomic analysis of hypoxia pathway is predictive of overall survival in Glioblastoma
Beig, N., Patel, J., Prasanna, P., Hill, V., Gupta, A., Correa, R., Bera, K., Singh, S., Partovi, S., Varadan, V., et al. (2018) · Scientific Reports · doi:10.1038/s41598-017-18310-0 · Cited by 157
Self-citationGuo, W., Li, H., Zhu, Y., Lan, L., Yang, S., Drukker, K., Morris, E. A., Burnside, E. S., Whitman, G. J., Giger, M. L., et al. (2015) · Journal of Medical Imaging · doi:10.1117/1.jmi.2.4.041007 · Cited by 148
Vaidya, P., Bera, K., Gupta, A., Wang, X., Corredor, G., Fu, P., Beig, N., Prasanna, P., Patil, P. D., Velu, P. D., et al. (2020) · The Lancet Digital Health · doi:10.1016/s2589-7500(20)30002-9 · Cited by 134
Self-citation
Cited by
Predicting cancer outcomes with radiomics and artificial intelligence in radiology
Bera, K., Braman, N., Gupta, A., Velcheti, V., & Madabhushi, A. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00560-7 · Cited by 819
Self-citationArtificial Intelligence for Predictive Biomarker Discovery in Immuno-Oncology: A Systematic Review
Prelaj, A., Miskovic, V., Zanitti, M., Trovo, F., Genova, C., Viscardi, G., Rebuzzi, S. E., Mazzeo, L., Provenzano, L., Kosta, S., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2023.10.125 · Cited by 340
Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours
Holder, A. M., Dedeilia, A., Sierra-Davidson, K., Cohen, S., Liu, D., Parikh, A., & Boland, G. M. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00705-7 · Cited by 298
Xu, Y., Su, G.-H., Ma, D., Xiao, Y., Shao, Z.-M., & Jiang, Y.-Z. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00729-7 · Cited by 163
“195 Another response is pseudoprogression, which is de fi ned as an increase in tumor size or newly identi fi ed lesion after treatment is initiated before a decrease in tumor size is observed.”
BackgroundThe artificial intelligence and machine learning in lung cancer immunotherapy
Gao, Q., Yang, L., Lu, M., Jin, R., Ye, H., & Ma, T. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01456-y · Cited by 148
Metadata
- Authors
- Vaidya, P., Bera, K., Patil, P. D., Gupta, A., Jain, P., Alilou, M., Khorrami, M., Velcheti, V., & Madabhushi, A.
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2020-10
- Volume
- 8
- Issue
- 2
- Pages
- e001343
- ISSN
- 2051-1426 (ISSN-L)
- OpenAlex
- W3092062217
- Cited by
- 117
- References
- 9
- FWCI
- 6.61
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel, non-invasive imaging approach to identify patients with advanced non-small cell lung cancer at risk of hyperprogressive disease with immune checkpoint blockade. https://app.cochat.ai/papers/10.1136/jitc-2020-001343
- The paper
- Vaidya, P., Bera, K., Patil, P. D., Gupta, A., Jain, P., Alilou, M., Khorrami, M., Velcheti, V., & Madabhushi, A. (2020). Novel, non-invasive imaging approach to identify patients with advanced non-small cell lung cancer at risk of hyperprogressive disease with immune checkpoint blockade. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2020-001343
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.